Participated · Series B · May 2019

Paradigm Diagnostics develops the Paradigm Cancer Diagnostic (PCDx), which uses proprietary sequencing, bioinformatics and technology to identify evidence-based treatment options that may improve a cancer patient’s progression-free survival. The company delivers comprehensive next-generation sequencing results, including mutational load, from a single slide and returns results in 3–5 business days. Led by co-founder, chairman and CEO David Mallery, Paradigm emphasizes rapid, clinically actionable genomic reporting. The recently announced financing will support rapid commercialization of the PCDx test. The article does not disclose revenue or user metrics. The company is based in Phoenix, AZ. Paradigm Diagnostics is a Phoenix, AZ-based developer of cancer diagnostic tests. It has developed PCDx, a clinical-grade NGS-based test designed to identify genomic and proteomic alterations in tumor DNA, RNA and protein to inform personalized cancer treatment. PCDx interrogates the most relevant genomic targets at over 5,000x average depth of coverage and reports 72 therapeutic associations, with results typically delivered in 4-5 business days. The company intends to use the funds from the Series B first close to build out its commercial team and establish research collaborations. The company is led by David Mallery, President and CEO.

Led · Equity · Dec 2016

Encounter Telehealth delivers telepsychiatry services and contracts with skilled nursing and other long‑term care facilities, and it also operates an outpatient clinic in western Nebraska. The company is a certified provider and derives most of its business from referrals; the majority of its patients are on Medicare. Encounter targets gaps in rural access to psychiatrists and aims to expand access for underserved populations with severe mental illness. Leadership cites AI‑powered tools as a future means to reduce administrative burdens and clinical staff burnout. Financially, the company is in the midst of a roughly $1 million fundraising reported via an SEC Form D filing; Prairie Ventures is a known backer and previously participated in an earlier round.

Participated · Series A · Mar 2015

PerceptiMed builds hardware and software that automates medication verification for retail pharmacies, hospitals, nursing homes and home health. Its flagship identRx uses machine vision to read manufacturer imprints on all sides of pills and the company claims a 99.9% error‑detection rate. The product line also includes a smaller MedPass unit for long‑term care with a locking device tied to patient RFID tags, a remote version of the system, and ScripClip tags for verified prescription bags. The platform integrates with pharmacy management systems and includes analytics to analyze near misses and identify root causes of errors. PerceptiMed was founded by CEO and co‑founder Dr. Alan Jacobs and co‑founder/COO Jenifer, with Jacobs developing the technology over two years in his garage. The company has begun work with national retail pharmacies and is pursuing expansion into the home‑health market while hiring across engineering, sales and marketing.